Robocath S.A.S

admin562025-08-31 23:49:50

Robocath S.A.S Company Overview

Robocath S.A.S is a French medical-robotics company founded on 9 October 2009 in Rouen, France. The company specializes in designing, developing, and commercializing robotic solutions for interventional cardiology and vascular disease treatment. Its flagship product, the R-ONE® system, is Europe’s first CE-marked robotic platform for percutaneous coronary intervention (PCI). In 2020, Robocath formed a strategic joint venture with Shanghai-based MicroPort MedBot (51% / 49%) to create Zhimai™ Robotics, introducing R-ONE® technology to China as the first commercially approved coronary-PCI robot following successful multi-center clinical trials.

Core Business and Key Technologies

Robocath’s core business focuses on developing vascular-intervention robots that improve precision, safety, and ergonomics in cath-labs. Proprietary technologies include master–slave robotic control, bionic dual-finger “twist & push” motion replicating human-hand manipulation, 0–360° continuous rotation and translation, sub-millimetric stepping accuracy, one-click locking for single-operator instrument exchange, and single-use sterile covers for rapid setup and infection control.

Market Position and Flagship Product

Robocath is recognized globally as a pioneer in interventional-cardiology robotics. Its leading product, R-ONE®, offers:

Up to 95% reduction in operator radiation exposure.
Shorter learning curves for new interventional cardiologists.
Compatibility with all standard PCI guidewires, balloons, and stents.
Support for remote PCI over 5G networks, demonstrated in transcontinental live procedures.

In partnership with MicroPort, Robocath has established localized manufacturing, training centers, and R&D programs in china, while expanding distribution across Europe, the Middle East, and Asia-Pacific.